Vendor Intelligence Report: Hunan Ruiwang Technology Center

Published 3 Jul 2026. 25-page investigative report on who is behind Hunan Ruiwang Technology Center: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 22 Finnrick lab tests, Hunan Ruiwang Technology Center posts 17 pass / 5 fail, an overall pass rate of 77%. The signal is product-specific: GHK-Cu is the cleanest current read, Retatrutide is deeper but imperfect, and Tirzepatide is the weak point. The full report also shows how Ruiwang's ratings move under stricter grading.

Ruiwang's public footprint is young and marketplace-led. eChemi presents the vendor as an active China-based Trader with 2024 establishment and large revenue claims, while hn-techcenter.com markets GMP-style cleanrooms and manufacturing capacity. Mainland registry confirmation was unavailable, and an adjacent UK Ruiwang company is an active dormant-style shell, not proof of Hunan ownership or UK recourse.

The sharpest listing-integrity issue is Tirzepatide. An eChemi sales page carried the wrong CAS and a structured category tied in the field record to Dromostanolone propionate before the URL later returned a guarded 403. That is not proof of a steroid shipment, but it is chemically wrong metadata on an injectable peptide listing.

COA posture improved cosmetically, not evidentially: the HNRW tab moved from empty placeholders to eight certificate images, but not lot-specific, lab-verifiable records. FDA DECRS returned no Ruiwang match, observed payment rails include wire/crypto-style routes with limited chargeback leverage, and the X/web affiliate scan found no public coupon or referral network.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 3 tested products
  • eChemi and HNRW captures comparing Trader status with manufacturing claims
  • Wrong-CAS Tirzepatide listing exhibits and the later 403 status
  • Companies House and FDA DECRS record checks
  • COA-tab image review, Certificate Transparency notes, and Faisco infrastructure leads
  • Shipping, payment, CBP enforcement context, and X/web affiliate sweep

Risk assessment

  • Tirzepatide quality-consistency risk — high: Tirzepatide has 4 Finnrick tests with 2 pass / 2 fail and a 75.36% rating; buyers should require current-lot third-party testing or move to a better-evidenced source.
  • Tirzepatide listing-mislabeling risk — high: An eChemi Tirzepatide page displayed CAS 521-12-0, associated with Dromostanolone propionate, before the URL returned 403 Forbidden.
  • U.S. import-enforcement risk — high: No FDA DECRS match was found for Ruiwang, and current CBP/SafeMedicines peptide-enforcement data directly affects U.S. buyers importing GLP-1 products.
  • Retatrutide quality-consistency risk — medium: Retatrutide is better evidenced than Tirzepatide but still shows 14 Finnrick tests with 11 pass / 3 fail and a 78.41% rating.
  • Manufacturing-claim and lot-verification risk — medium: eChemi classifies Ruiwang as a Trader while the HNRW site claims GMP and cleanroom capabilities; current COA images are not lot-verifiable documentation.
  • Payment and seizure-recourse risk — medium: Observed payment routes include wire, crypto, Cash App, Wise, and Binance, leaving limited chargeback or seizure recourse for buyers.